Men use preventive health services at significantly lower rates than women — and cancer screening is part of that pattern. Some of it is structural (women have built-in annual gynecological visits), some cultural, and some stems from genuine confusion, particularly around prostate cancer screening, where guidelines from different organizations say contradictory things.
This guide covers every cancer screening relevant to men: prostate (including the PSA controversy, explained clearly), testicular cancer awareness, colorectal cancer, lung cancer, and skin cancer. By the end, you’ll know what to schedule, when, and why — and you’ll understand the prostate debate well enough to have an informed conversation with your doctor.
Prostate Cancer Screening: Understanding the PSA Controversy
Prostate cancer is the most common cancer in US men (excluding skin cancer) and the second leading cause of cancer death, after lung cancer. Approximately 1 in 8 men (12.5%) will develop it during their lifetime, with about 299,000 new cases projected in 2024.
Despite this burden, prostate cancer screening is genuinely controversial — not because guideline writers are being overly cautious, but because the screening test (PSA, or prostate-specific antigen) has real limitations that distinguish it from most other screening tools.
Why PSA Screening Is Controversial
PSA is a protein produced by both normal and cancerous prostate cells. An elevated PSA level (traditionally above 4.0 ng/mL) is associated with increased cancer risk — but also with benign prostatic hyperplasia (BPH), prostatitis, and other non-cancerous conditions. The core problem: approximately 75% of elevated PSA results that lead to prostate biopsy do NOT find cancer. That is a high false positive rate.
The second problem is overdiagnosis. PSA screening detects many low-grade prostate cancers that grow so slowly they would never cause symptoms or death in the patient’s lifetime. Finding and treating these cancers exposes men to serious treatment side effects (urinary incontinence, erectile dysfunction from prostatectomy or radiation) with no meaningful benefit. This is the harm guideline bodies are weighing against the benefit of catching aggressive cancers early.
What Shared Decision-Making Means in Practice
“Shared decision-making” means something specific: your doctor explains the potential benefit (detecting aggressive cancer early) and the potential harms (false positives; overdiagnosis), and you decide together whether PSA testing makes sense given your values and risk profile.
ACS 2023: Average risk: discuss PSA at age 50. High risk (Black men; first-degree relative with prostate cancer before 65): age 45. Very high risk (multiple first-degree relatives): age 40.
If You Decide to Test: What the Numbers Mean
- PSA below 2.5 ng/mL: Retest every 2 years (ACS)
- PSA 2.5–4.0 ng/mL: Annual testing
- PSA above 4.0 ng/mL: Discussion about biopsy vs. additional evaluation
A single elevated PSA is not a diagnosis. Factors that refine interpretation include PSA velocity (how quickly it’s rising), PSA density (PSA relative to prostate volume on imaging), and the free-to-total PSA ratio. Newer tools — PHI (Prostate Health Index), 4Kscore, and multiparametric MRI — help identify which men actually need biopsy, reducing the number performed for ultimately benign PSA elevations.
Active Surveillance for Low-Grade Disease
Men diagnosed with low-grade prostate cancer (Gleason grade group 1, PSA <10) are often managed with active surveillance — regular PSA checks, MRI, and periodic biopsies — rather than immediate treatment. Evidence supports this approach as safe for appropriately selected low-grade cancers, avoiding treatment side effects with no survival compromise.
Black Men and Prostate Cancer: A Higher-Stakes Conversation
Black men in the US have approximately 1.7 times the prostate cancer incidence of white men and 2.1 times the mortality rate. They are diagnosed at younger ages with more aggressive disease more frequently. Despite this, Black men were underrepresented in the major prostate cancer screening trials, meaning the evidence base was not developed with them in mind.
This is why both ACS and the American Urological Association recommend that Black men begin the shared decision-making discussion at age 45, rather than 50.
Testicular Cancer: Awareness in Your 20s and 30s
Testicular cancer is the most common solid tumor in men between the ages of 20 and 34. About 9,600 new cases are projected in 2024. The good news: it is also one of the most treatable cancers — overall 5-year survival is approximately 95%, and for stage I (localized) disease it approaches 99%.
USPSTF does not recommend routine testicular cancer screening (Grade D). But awareness matters. Most testicular cancers are found by men themselves or their partners, and early-stage discovery significantly simplifies treatment.
Warning Signs to Know
See a doctor promptly — with ultrasound evaluation — if you notice any of the following:
- A painless lump or swelling in a testicle (painless is actually the rule, not the exception)
- A feeling of heaviness in the scrotum
- A dull ache in the lower abdomen or groin
- A sudden collection of fluid in the scrotum
- Breast tenderness or swelling (some tumors produce hCG, causing gynecomastia)
A delay in evaluation after noticing a lump is the main factor that causes worse staging at diagnosis. Risk factors include cryptorchidism (undescended testicle), personal or family history of testicular cancer, and Klinefelter syndrome.
Colorectal Cancer Screening: What Men Need to Know
Colorectal cancer is the third most common cancer in men. Men have higher CRC incidence than women — and are less likely to complete screening. This is a gap worth closing.
Annual FIT — at-home stool blood test; positive result requires colonoscopy
Colonoscopy every 10 years — allows polyp removal during procedure
Cologuard (stool DNA) every 1–3 years — more sensitive; higher false positive rate
CT colonography every 5 years — no sedation; polyp ≥6mm requires follow-up
First-degree relative with CRC before 60: Begin at 40 or 10 years before relative’s diagnosis, colonoscopy q5y.
Lynch syndrome: Colonoscopy q1–2 years from age 20–25.
Stop ages: Grade A through 75; individualized 76–85; stop at 86+ (USPSTF).
A first colonoscopy with no findings at 45 means the next one isn’t due until 55. The procedure takes about 30 minutes — the bowel preparation the day before is the harder part for most men.
Lung Cancer Screening: The Leading Killer
Lung cancer is the leading cause of cancer death in men, responsible for more than 65,000 male deaths annually. Smoking accounts for approximately 80–85% of lung cancers.
Pack-years: packs per day × years smoked. 1 pack/day × 20 years = 20 pack-years. Annual LDCT only — not chest X-ray, which has been shown ineffective for lung cancer screening.
Lung screening should be paired with referral to smoking cessation support. Quitting remains the most impactful single action for reducing lung cancer risk — LDCT is a complement, not a substitute.
Skin Cancer: Men’s Blind Spot
Men over 50 have higher melanoma incidence and mortality rates than women of the same age — melanoma mortality rates are approximately twice as high in men as in women. Men are less likely to use sunscreen, less likely to see a dermatologist, and more likely to have prolonged outdoor occupational exposure.
USPSTF does not recommend routine skin cancer screening (Grade I). However, the American Cancer Society recommends annual skin examination by a dermatologist and monthly self-examination using the ABCDE criteria: Asymmetry, Border irregularity, Color variation, Diameter greater than 6mm, and Evolution (any change in size, shape, color, or new symptoms like bleeding or itching).
A practical note: ask your partner to periodically check areas you can’t easily see — the back, back of the neck, and scalp (especially if hair is thinning).
Other Cancers Men Should Know About
HPV Vaccination for Men
The HPV vaccine (Gardasil 9) protects men against HPV-related cancers including anal cancer, oropharyngeal (throat) cancer, penile cancer, and genital warts. ACIP recommends vaccination for all males through age 26. For men ages 27–45, shared decision-making with a provider is recommended — less effective after likely HPV exposure but still beneficial if not previously vaccinated.
Anal Cancer and Higher-Risk Men
Anal cancer is significantly more common in men who have sex with men (MSM), particularly those who are HIV-positive. HPV types 16 and 18 are the primary drivers. NCCN and specialist societies recommend high-resolution anoscopy (HRA) surveillance for HIV-positive MSM and some HIV-negative MSM with high-risk history. If you are in this risk group, ask specifically about anal cancer surveillance.
Men’s Complete Cancer Screening Schedule
| Cancer | Start Age | Frequency | Source |
|---|---|---|---|
| Colorectal | 45 | FIT annually or colonoscopy q10y | USPSTF/ACS |
| Prostate (PSA) | 50 avg (ACS); 55 (USPSTF); 45 Black men | Shared decision-making; if testing: q2y or annual | ACS/USPSTF |
| Lung (smokers) | 50 | Annual LDCT | USPSTF 2021 |
| Testicular | — | No routine screening; prompt evaluation of any scrotal lump | — |
| Skin | All ages | Annual derm exam (ACS); monthly self-exam | ACS |
Why Men Skip Screening and What Changes That
Research consistently shows men are less likely than women to have a primary care provider, to schedule preventive health visits, or to complete cancer screenings. Reasons include minimizing symptoms, lower perceived risk, and simply not having a regular doctor.
What actually changes this: having a trusted primary care provider and maintaining an annual visit. Cancer screening is not a separate appointment — it happens within a relationship with a provider who knows your history and can personalize recommendations. For men without a primary care provider, federally qualified health centers offer sliding-scale care. The investment of establishing care is worth making before you need it urgently.
Frequently Asked Questions
Should I get a PSA test for prostate cancer?
That depends on your age, risk level, and values — which is exactly why USPSTF characterizes it as a shared decision rather than a routine recommendation. For average-risk men ages 55–69, evidence shows a modest mortality benefit from PSA screening but also meaningful harms from false positives and overdiagnosis. ACS recommends having the conversation at 50. For Black men or those with a first-degree relative with prostate cancer before 65, the conversation should happen at 45. Discuss potential benefits and harms with your provider and decide based on your personal priorities.
At what age do men start prostate cancer screening?
There is no universal start age because prostate cancer screening involves shared decision-making. ACS recommends the discussion begin at age 50 for average-risk men (life expectancy ≥10 years), at 45 for Black men and those with a first-degree relative with prostate cancer before 65, and at 40 for men with multiple first-degree relatives with early prostate cancer. USPSTF recommends offering the discussion to men ages 55–69 only. Men 70 and older are generally advised against PSA screening by USPSTF (Grade D).
What PSA number might mean I have prostate cancer?
The traditional threshold for further evaluation is PSA above 4.0 ng/mL — but context matters enormously. PSA rises normally with age, prostate size, after exercise or ejaculation, and with benign prostate conditions. An isolated elevated PSA is never a diagnosis — it is a signal that additional evaluation is warranted. About 75% of men who undergo biopsy for elevated PSA do not have cancer. Newer tools (PHI, 4Kscore, mpMRI) help determine which elevated PSA values actually need biopsy.
Do men need a colonoscopy at 45?
Yes, if you are average risk. USPSTF and ACS both recommend beginning colorectal cancer screening at age 45. Colonoscopy every 10 years is one option, but not the only one — annual FIT (fecal immunochemical test) is equally recommended, avoids sedation and bowel prep, and is highly effective when done consistently each year. A positive FIT requires follow-up colonoscopy. Men at higher risk (first-degree relative with CRC before 60) should begin colonoscopy at 40.
Is there a cancer screening test for men in their 20s and 30s?
For average-risk men under 45, there are no USPSTF-recommended routine cancer screening tests. The focus in this age group is awareness — particularly testicular cancer. Testicular cancer is the most common solid tumor in men ages 20–34 and is highly curable if detected early. No formal screening test exists, but any painless scrotal lump or swelling warrants prompt ultrasound evaluation. Don’t wait to see if it resolves on its own.
What cancers are Black men most at risk for?
Black men have significantly elevated risk for prostate cancer (1.7× higher incidence, 2.1× higher mortality than white men), colorectal cancer, and lung cancer. For prostate cancer specifically, ACS and AUA recommend beginning the PSA shared decision-making discussion at age 45 rather than 50. Maintaining annual primary care visits and completing all age-appropriate screenings on schedule is especially important.
Does the HPV vaccine help men?
Yes. The HPV vaccine (Gardasil 9) protects men against HPV types that cause anal cancer, oropharyngeal cancer, penile cancer, and genital warts. ACIP recommends vaccination for all males through age 26. For men ages 27–45, shared decision-making is recommended. The vaccine is most effective before potential HPV exposure, but still provides protection in people not yet exposed to all covered types. Men who have sex with men and HIV-positive individuals are among those with the greatest benefit.
- US Preventive Services Task Force (USPSTF) — Prostate (2018), CRC (2021), Lung (2021) recommendations.
- American Cancer Society — Prostate Early Detection (2023), CRC (2018), Lung (2023), Cancer Facts & Figures 2024.
- American Urological Association (AUA) — Prostate Cancer Early Detection Guideline, 2023.
- NCI SEER Database — cancer statistics by sex, age, and race/ethnicity.
- ACIP — HPV Vaccination Schedule and Recommendations (2019 update).
- European Randomized Study of Screening for Prostate Cancer (ERSPC), Schröder FH et al.